Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.77 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | TTR | P02766 | 1/20 | 0.58 |
| ▸ | TYR | P14679 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Shinpterocarpin SCHEMBL30001940 | 1.00 | MGAM (0.77) | MGAMPTPN1CYP3A4NPC1HSP90AA1 | |
| Phaseolin SCHEMBL29929606 | 0.87 | MGAM (1.00) | MGAMPTPN1CYP3A4NPC1HSP90AA1 | |
| Phaseolin SCHEMBL33736 | 0.87 | MGAM (1.00) | MGAMPTPN1CYP3A4NPC1HSP90AA1 | |
| Phaseolin SCHEMBL33735 | 0.87 | MGAM (1.00) | MGAMPTPN1CYP3A4NPC1HSP90AA1 | |
| Phaseolin SCHEMBL29351585 | 0.87 | MGAM (1.00) | MGAMPTPN1CYP3A4NPC1HSP90AA1 | |
| Phaseolin SCHEMBL28856370 | 0.86 | MGAM (0.98) | MGAMPTPN1CYP3A4NPC1HSP90AA1 | |
| SCHEMBL13794192 | 0.85 | MGAM (0.59) | MGAMPTPN1CYP3A4NPC1HSP90AA1 | |
| Leiocarpin SCHEMBL29352437 | 0.85 | MGAM (0.59) | MGAMPTPN1CYP3A4NPC1HSP90AA1 | |
| Phaseolin SCHEMBL28201435 | 0.83 | MGAM (0.90) | MGAMPTPN1CYP3A4NPC1HSP90AA1 | |
| Phaseolin SCHEMBL28209786 | 0.82 | MGAM (0.89) | MGAMPTPN1CYP3A4NPC1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102653-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2024-10-01 | — | — | US | disclosed |
| US-20240000841-A1 | LIGAND REGULATED PROTEIN-PROTEIN INTERACTION SYSTEM | ST ANNA KINDERKREBSFORSCHUNG (AT) | 2024-01-04 | — | — | US | disclosed |
| US-11844813-B2 | Ligand regulated protein-protein interaction system | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2023-12-19 | — | — | US | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | MGAM 2470/4885PTPN1 1563/4885CYP3A4 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.